Literature DB >> 28795653

Reliability of the SF-36 in Japanese patients with systemic lupus erythematosus and its associations with disease activity and damage: a two-consecutive year prospective study.

S Baba1, Y Katsumata1, Y Okamoto1, Y Kawaguchi1, M Hanaoka1, H Kawasumi1, H Yamanaka1.   

Abstract

We aimed to validate the reliability of the Medical Outcomes Study Short Form-36 (SF-36) among Japanese patients with systemic lupus erythematosus (SLE). Japanese patients with SLE ( n = 233) completed the SF-36 and other related demographic questionnaires, and physicians simultaneously completed the SLE Disease Activity Index 2000 (SLEDAI-2K) and the Systemic Lupus International Collaborating Clinics Damage Index (SDI). Patients were prospectively followed for a repeat assessment the following year. The SF-36 subscales demonstrated acceptable internal consistency (Cronbach's α of 0.85-0.89), and an overall good test-retest reliability (intraclass correlation coefficient >0.70). The average baseline SF-36 subscale/summary scores except for "bodily pain" were significantly lower than those of the Japanese general population ( p < 0.05). The SDI showed an inverse correlation with the SF-36 subscale/summary scores except for "vitality" and "mental component summary" at baseline, whereas the SLEDAI-2K did not. In the second year, "social functioning" and "mental component summary" of the SF-36 deteriorated among patients whose SDI or SLEDAI-2K score increased (effect sizes < -0.20). In conclusion, the SF-36 demonstrated acceptable reliability among Japanese patients with SLE. Health-related quality of life measured by the SF-36 was reduced in Japanese patients with SLE and associated with disease damage, rather than disease activity.

Entities:  

Keywords:  Systemic lupus erythematosus; outcome measures; quality of life

Mesh:

Year:  2017        PMID: 28795653     DOI: 10.1177/0961203317725586

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  6 in total

1.  Association of HSP90B1 genetic polymorphisms with efficacy of glucocorticoids and improvement of HRQoL in systemic lupus erythematosus patients from Anhui Province.

Authors:  Xiu-Xiu Sun; Su-Su Li; Man Zhang; Qiao-Mei Xie; Jian-Hua Xu; Sheng-Xiu Liu; Yuan-Yuan Gu; Fa-Ming Pan; Jin-Hui Tao; Sheng-Qian Xu; Shuang Liu; Jing Cai; De-Guang Wang; Long Qian; Chun-Huai Wang; Li Lian; Hui Xiao; Pei-Ling Chen; Chun-Mei Liang; You-Bing Fang; Qiang Zhou; Hai-Liang Huang; Hong Su; Hai-Feng Pan; Dong-Qing Ye; Yan-Feng Zou
Journal:  Am J Clin Exp Immunol       Date:  2018-04-05

2.  Patient-Reported Outcomes Predict Mortality in Lupus.

Authors:  Desiree R Azizoddin; Meenakshi Jolly; Shilpa Arora; Ed Yelin; Patricia Katz
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-07-13       Impact factor: 4.794

3.  Measurement properties of selected patient-reported outcome measures for use in randomised controlled trials in patients with systemic lupus erythematosus: a systematic review.

Authors:  Vibeke Strand; Lee S Simon; Alexa Simon Meara; Zahi Touma
Journal:  Lupus Sci Med       Date:  2020-06

4.  Association of physical fitness components and health-related quality of life in women with systemic lupus erythematosus with mild disease activity.

Authors:  Blanca Gavilán-Carrera; Jaqueline Garcia da Silva; José A Vargas-Hitos; José M Sabio; Pablo Morillas-de-Laguno; Raquel Rios-Fernández; Manuel Delgado-Fernández; Alberto Soriano-Maldonado
Journal:  PLoS One       Date:  2019-02-20       Impact factor: 3.240

5.  The ability of different imputation methods for missing values in mental measurement questionnaires.

Authors:  Xueying Xu; Leizhen Xia; Qimeng Zhang; Shaoning Wu; Mingcheng Wu; Hongbo Liu
Journal:  BMC Med Res Methodol       Date:  2020-02-27       Impact factor: 4.615

6.  Comparison of performance of specific (SLEQOL) and generic (SF36) health-related quality of life questionnaires and their associations with disease status of systemic lupus erythematosus: a longitudinal study.

Authors:  Worawit Louthrenoo; Nuntana Kasitanon; Eric Morand; Rangi Kandane-Rathnayake
Journal:  Arthritis Res Ther       Date:  2020-01-10       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.